Traws Pharma, Inc. (NASDAQ:TRAW) Sees Significant Decline in Short Interest

Traws Pharma, Inc. (NASDAQ:TRAW) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 1,700 shares, a drop of 92.7% from the August 31st total of 23,400 shares. Based on an average daily volume of 5,200 shares, the short-interest ratio is presently 0.3 days.

Traws Pharma Trading Down 0.5 %

Shares of TRAW traded down $0.04 during mid-day trading on Wednesday, reaching $7.40. The company had a trading volume of 799 shares, compared to its average volume of 4,524. The business’s 50 day moving average price is $0.66. Traws Pharma has a 1-year low of $6.01 and a 1-year high of $27.50.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($4.87) earnings per share for the quarter. Traws Pharma had a negative net margin of 60,641.14% and a negative return on equity of 144.95%. The company had revenue of $0.06 million during the quarter. On average, equities analysts forecast that Traws Pharma will post -146 EPS for the current year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.